Log in

NASDAQ:AMEDAmedisys Stock Price, Forecast & News

$204.14
-1.49 (-0.72 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$201.10
Now: $204.14
$208.97
50-Day Range
$169.77
MA: $187.06
$205.63
52-Week Range
$118.79
Now: $204.14
$218.44
Volume366,180 shs
Average Volume335,792 shs
Market Capitalization$6.61 billion
P/E Ratio53.16
Dividend YieldN/A
Beta0.95
Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks. The Hospice segment offers care that is designed to provide comfort and support for those who are dealing with a terminal illness, including heart disease, pulmonary disease, Alzheimer's, HIV/AIDS, and cancer. The Personal Care segment provides assistance for patients with the activities of daily living. As of February 27, 2019, the company owned and operated 472 care centers in 38 states. Amedisys, Inc. was founded in 1982 and is headquartered in Baton Rouge, Louisiana.
Read More
Amedisys logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.34 out of 5 stars


Industry, Sector and Symbol

Industry Home health care services
Sub-IndustryHealth Care Services
SectorMedical
Current SymbolNASDAQ:AMED
CUSIP02343610
Phone225-292-2031

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.96 billion
Cash Flow$6.17 per share
Book Value$19.89 per share

Profitability

Net Income$126.83 million

Miscellaneous

Employees21,300
Market Cap$6.61 billion
Next Earnings Date7/29/2020 (Estimated)
OptionableOptionable

Receive AMED News and Ratings via Email

Sign-up to receive the latest news and ratings for AMED and its competitors with MarketBeat's FREE daily newsletter.

Amedisys (NASDAQ:AMED) Frequently Asked Questions

How has Amedisys' stock been impacted by COVID-19 (Coronavirus)?

Amedisys' stock was trading at $170.47 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AMED stock has increased by 19.8% and is now trading at $204.14. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Amedisys?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last year. There are currently 4 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Amedisys.

When is Amedisys' next earnings date?

Amedisys is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for Amedisys.

How were Amedisys' earnings last quarter?

Amedisys Inc (NASDAQ:AMED) announced its quarterly earnings results on Wednesday, May, 6th. The health services provider reported $1.05 EPS for the quarter, topping the Zacks' consensus estimate of $0.97 by $0.08. The health services provider had revenue of $491.70 million for the quarter, compared to analyst estimates of $507.45 million. Amedisys had a net margin of 6.43% and a return on equity of 23.09%. The company's revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period last year, the firm earned $1.11 EPS. View Amedisys' earnings history.

What price target have analysts set for AMED?

14 brokerages have issued 12-month price objectives for Amedisys' stock. Their forecasts range from $125.00 to $240.00. On average, they anticipate Amedisys' stock price to reach $191.43 in the next year. This suggests that the stock has a possible downside of 6.2%. View analysts' price targets for Amedisys.

Has Amedisys been receiving favorable news coverage?

News stories about AMED stock have trended somewhat positive this week, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Amedisys earned a media sentiment score of 0.7 on InfoTrie's scale. They also assigned news stories about the health services provider a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news about Amedisys.

Are investors shorting Amedisys?

Amedisys saw a increase in short interest during the month of June. As of June 15th, there was short interest totaling 1,200,000 shares, an increase of 8.1% from the May 31st total of 1,110,000 shares. Based on an average trading volume of 318,000 shares, the short-interest ratio is currently 3.8 days. Currently, 3.8% of the company's stock are sold short. View Amedisys' Current Options Chain.

Who are some of Amedisys' key competitors?

What other stocks do shareholders of Amedisys own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amedisys investors own include Alibaba Group (BABA), NVIDIA (NVDA), Adobe (ADBE), Cisco Systems (CSCO), Netflix (NFLX), CVS Health (CVS), Intel (INTC), Micron Technology (MU), Pfizer (PFE) and Vertex Pharmaceuticals (VRTX).

Who are Amedisys' key executives?

Amedisys' management team includes the following people:
  • Mr. Paul Berthold Kusserow, Pres, CEO & Director (Age 58)
  • Mr. Scott G. Ginn, Chief Financial Officer (Age 50)
  • Mr. Christopher T. Gerard, Chief Operating Officer (Age 52)
  • Mr. David L. Kemmerly, Sr. VP of Gov. Affairs & Gen. Counsel (Age 56)
  • Ms. Sharon Brunecz, Chief HR Officer (Age 52)

What is Amedisys' stock symbol?

Amedisys trades on the NASDAQ under the ticker symbol "AMED."

How do I buy shares of Amedisys?

Shares of AMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Amedisys' stock price today?

One share of AMED stock can currently be purchased for approximately $204.14.

How big of a company is Amedisys?

Amedisys has a market capitalization of $6.61 billion and generates $1.96 billion in revenue each year. The health services provider earns $126.83 million in net income (profit) each year or $4.40 on an earnings per share basis. Amedisys employs 21,300 workers across the globe.

What is Amedisys' official website?

The official website for Amedisys is www.amedisys.com.

How can I contact Amedisys?

Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The health services provider can be reached via phone at 225-292-2031 or via email at [email protected]

This page was last updated on 7/3/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.